Loading…
Loading…
WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.1 The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP. This marks the first time the European Commission has granted orphan designation recognition for a drug to treat GPP in the European Union (EU).
NEREUS⢠Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. PR Newswire WASHI
WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick Schumacher, is set to compete this weekend in the inaugural Freedom 250 Grand Prix of Washington, D.C.
PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.
Vanda Pharmaceuticals Inc. (VNDA) Q2 2026 Earnings Call Transcript
Arrowstreet Capital Limited Partnership purchased a new stake in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 241,430 shares of the biopharmaceutical company's stock, valued at approximately $1,668,000. Arrowstreet Capital Limited Partnership owned approximately
Vanda Pharmaceuticals (NASDAQ: VNDA) reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it expects operating expenses to begin declining late this year, with more
Vanda Pharmaceuticals NASDAQ: VNDA reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it expects operating expenses to begin declining late this year, with more substantial reductions anticipated in 2027.